NFG
AUPH icon

Norris Financial Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Norris Financial Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.81M Sell
342,331
-146
-0% -$2.33K 2.31% 13
2026
Q1 		$5.08M Sell
342,477
-3,535
-1% -$51.7K 1.66% 18
2025
Q4 		$5.52M Buy
346,012
+1,142
+0.3% +$16.2K 1.88% 12
2025
Q3 		$3.81M Sell
344,870
-4,765
-1% -$52K 1.39% 20
2025
Q2 		$2.96M Sell
349,635
-38,208
-10% -$306K 1.21% 28
2025
Q1 		$3.12M Sell
387,843
-20,909
-5% -$169K 1.46% 16
2024
Q4 		$3.67M Sell
408,752
-8,762
-2% -$71.5K 1.72% 15
2024
Q3 		$3.06M Sell
417,514
-8,887
-2% -$55.1K 1.51% 15
2024
Q2 		$2.43M Sell
426,401
-8,433
-2% -$44.4K 1.27% 23
2024
Q1 		$2.18M Buy
434,834
+31,510
+8% +$214K 1.2% 24
2023
Q4 		$3.63M Sell
403,324
-6,875
-2% -$56.6K 2.2% 12
2023
Q3 		$3.19M Buy
410,199
+3,169
+0.8% +$31K 2.21% 12
2023
Q2 		$3.94M Buy
407,030
+3,209
+0.8% +$33.3K 2.73% 11
2023
Q1 		$4.43M Sell
403,821
-6,019
-1% -$53K 3.25% 9
2022
Q4 		$1.77M Sell
409,840
-10,194
-2% -$59.1K 1.5% 20
2022
Q3 		$3.16M Buy
420,034
+8,029
+2% +$69.5K 2.89% 12
2022
Q2 		$4.14M Buy
412,005
+22,546
+6% +$252K 3.33% 12
2022
Q1 		$4.82M Buy
389,459
+39,310
+11% +$608K 2.91% 14
2021
Q4 		$8.01M Buy
350,149
+51,919
+17% +$1.23M 4.83% 4
2021
Q3 		$6.6M Buy
298,230
+17,170
+6% +$272K 4.36% 5
2021
Q2 		$3.64M Buy
281,060
+47,123
+20% +$600K 2.46% 15
2021
Q1 		$3.04M Buy
233,937
+141,782
+154% +$2.06M 2.23% 17
2020
Q4 		$1.27M Buy
92,155
+2,841
+3% +$41.3K 1% 26
2020
Q3 		$1.32M Buy
89,314
+4,727
+6% +$68.5K 1.11% 25
2020
Q2 		$1.37M Buy
84,587
+19,301
+30% +$309K 1.3% 18
2020
Q1 		$947K Buy
65,286
+10,758
+20% +$190K 1.05% 25
2019
Q4 		$1.1M Buy
+54,528
New +$502K 1.02% 24

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norris Financial Group's AUPH Position: Q2 2026 in Review

Norris Financial Group reduced its Aurinia Pharmaceuticals (AUPH) stake by 0.04% in Q2 2026, selling an estimated $2.33K and leaving 342,331 shares worth $5.81M. The position accounts for 2.31% of the portfolio, ranked #13.

Norris Financial Group first reported a position in AUPH in Q4 2019 and has held it in 27 quarters since. The position peaked at $8.01M in Q4 2021. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Norris Financial Group held 342,331 shares of Aurinia Pharmaceuticals worth $5.81M as of Q2 2026.
  • Norris Financial Group sold 146 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $2.33K.
  • Aurinia Pharmaceuticals made up 2.31% of Norris Financial Group's portfolio in Q2 2026, its #13 holding.
  • Norris Financial Group first reported a position in Aurinia Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Norris Financial Group's Aurinia Pharmaceuticals position peaked at $8.01M in Q4 2021.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Norris Financial Group's 13F filing for Q2 2026, filed 5 Aug 2026.